Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP4 | P49662 | 1/20 | 0.50 |
| ▸ | CASP5 | P51878 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28269086 | 0.89 | LSS (0.66) | ALDH1A1KDM4ELSSTSHRHPGD | |
| SCHEMBL11955028 | 0.88 | HPGD (0.69) | ALDH1A1KDM4ETSHRHPGDCYP3A4 | |
| SCHEMBL2056150 | 0.84 | MC4R (0.66) | ALDH1A1KDM4ELSSHPGDCASP1 | |
| SCHEMBL3994683 | 0.81 | HRH3 (0.67) | ALDH1A1KDM4ELSSHPGDCASP1 | |
| SCHEMBL10294628 | 0.81 | HRH3 (0.70) | CYP3A4POLBMEN1KMT2ASIGMAR1 | |
| SCHEMBL8229397 | 0.79 | PKM (0.52) | ALDH1A1KDM4ELSSTSHRHPGD | |
| SCHEMBL10294004 | 0.79 | LSS (0.51) | ALDH1A1KDM4ELSSTSHRHPGD | |
| SCHEMBL28799508 | 0.79 | KDM4E (0.54) | ALDH1A1KDM4ELSSTSHRHPGD | |
| SCHEMBL13442 | 0.79 | HRH3 (0.71) | ALDH1A1KDM4ELSSHPGDCASP1 | |
| SCHEMBL1045589 | 0.79 | SIGMAR1 (0.78) | ALDH1A1KDM4EPOLBNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313096-A1 | NEW COMPOUNDS V | AstraZeneca AB (Publ) (SE) | 2011-04-27 | — | — | EP | claimed |
| WO-2009147211-A1 | NEW COMPOUNDS V | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| EP-2350083-B1 | PYRIMIDO[5,4-D]PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | NANTBIO, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20120264759-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-7858782-B2 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | ALDH1A1 213/4885KDM4E 4209/4885LSS 799/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | ALDH1A1 4081/4885KDM4E 3621/4885LSS 3907/4885 |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | IL5, IKZF3, CYP11B2 | ALDH1A1 360/4885KDM4E 4349/4885LSS 776/4885 |
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | ALDH1A1 3032/4885KDM4E 1623/4885LSS 4642/4885 |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | ALDH1A1 3351/4885KDM4E 2463/4885LSS 3607/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | ALDH1A1 3032/4885KDM4E 1623/4885LSS 4642/4885 |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | SLC10A1, GLS, SLC10A2 | ALDH1A1 494/4885KDM4E 4469/4885LSS 1243/4885 |
| US-20120264759-A1 | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, BAZ2B, PRKCZ | ALDH1A1 4143/4885KDM4E 2187/4885LSS 3703/4885 |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | MAP3K2, MAP3K5, MAP4K2 | ALDH1A1 3921/4885KDM4E 2636/4885LSS 3757/4885 |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, CAMKK2, BAZ1A | ALDH1A1 3429/4885KDM4E 3203/4885LSS 3602/4885 |
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | UCK2, ULK2, ULK1 | ALDH1A1 3580/4885KDM4E 2084/4885LSS 4424/4885 |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | MAP3K15, DSTYK, STK25 | ALDH1A1 4099/4885KDM4E 1292/4885LSS 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.